Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company serves both livestock animals, including cattle, swine, poultry, fish, and sheep, as well as companion animals such as dogs, cats, and horses. Its product portfolio includes vaccines that prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce specific immune responses; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that eliminate external and internal parasites such as fleas, ticks, and worms. Zoetis also offers pharmaceutical products for pain and sedation, antiemetic, reproductive, and oncology applications; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives for livestock. Additionally, the company provides portable blood and urine analysis testing, point-of-care diagnostic products, instruments, reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors. Its non-pharmaceutical offerings include nutritionals, agribusiness services, biodevices, genetic tests, and precision animal health products. The company markets its products to veterinarians, livestock producers, and retail outlets through sales representatives and technical and veterinary operations specialists. Founded in 1952, Zoetis is headquartered in Parsippany, New Jersey.
| Symbol | ZTS |
|---|---|
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| CEO | Kristin C. Peck |
| Employees | 13800 |
| Headquarters | Parsippany, NJ, US |
| IPO | 2013-02-01 |
| Website | www.zoetis.com |